OpenAI CEO of AGI Deployment Fidji Simo is taking medical leave, effective immediately. In a memo to staff published by The Verge on April 3, Simo said she has POTS, a neuroimmune condition affecting blood circulation that relapsed weeks before she started at OpenAI last August. "For my entire time here, I have postponed medical tests and new therapies to stay completely focused on the job and not miss a single day of work," she wrote.
Greg Brockman, OpenAI's president, will oversee product during her absence. The same day, Brad Lightcap, OpenAI's chief operating officer, announced he is stepping down from the COO role to focus on special projects reporting directly to CEO Sam Altman. Denise Dresser, a former Slack chief executive and OpenAI's chief revenue officer, will take over most of Lightcap's responsibilities.
Kate Rouch, OpenAI's chief marketing officer, also departed last week to focus on recovery from late-stage breast cancer, diagnosed roughly a year and a half ago, according to CNBC.
The announcements landed three days after OpenAI disclosed a $122 billion funding round at an $852 billion post-money valuation, one of the largest private capital raises in history. Amazon has committed $50 billion to the round, with $35 billion contingent on OpenAI completing an IPO or reaching AGI before a year-end deadline outlined in its financing agreements. OpenAI says it is currently generating $2 billion in revenue per month, has nearly 1 billion weekly active users, and has crossed 50 million paying subscribers, according to OpenAI's VP of ChatGPT.
What OpenAI did not say: none of these departures were disclosed in advance to investors, enterprise customers, or the banks underwriting its prospective IPO. The simultaneous exit of the executive in charge of deploying the company's core mission and the executive running its commercial operation, from an $852 billion entity weeks from a public offering, with no advance warning to the parties with the most financial exposure, is at minimum a disclosure failure. OpenAI declined to comment on the disclosure timeline.
Simo joined OpenAI in August 2025 from Instacart, where she was CEO from 2021 through mid-2025. Before that she spent a decade at Meta. In 2025 she co-founded ChronicleBio, a biomedical research company focused on neuroimmune disorders including POTS, ME/CFS, and Long COVID, according to Wikipedia. She also co-founded the Metrodora Institute, a clinic treating infection-associated chronic conditions, which closed after roughly two years last year.
The timing is not incidental. Simo was the executive tasked with deploying AGI, the company's stated purpose. Lightcap was running the commercial operation. Their departures within 72 hours of each other, with no pre-disclosure to capital market participants, tracks a pattern.
Jan Leike, OpenAI's former safety chief, left in 2024 saying safety had taken a backseat to shipping products. Ilya Sutskever, a co-founder and former chief scientist, departed citing a personally meaningful project. Rouch is recovering from cancer. Simo postponed treatment to keep working. The industry's pace is breaking the people who run it.
Amazon's $35 billion contingent tranche adds another pressure. According to Amazon's SEC 8-K filing, the obligations terminate if Amazon has not invested the full commitment by December 31, 2028 — a deadline that also ties to specified OpenAI milestones, including an IPO or a defined AGI threshold. Roughly two years out, whoever inherits Simo's and Lightcap's responsibilities is working against a clock most capital market participants were not told to watch.